Glibenclamide therapy in diabetes mellitus

Area of Science:

• Endocrinology
• Pharmacology

Background:

• Maturity onset diabetes mellitus (MODY) requires effective glycemic control.
• Sulfonylurea drugs are a common treatment for type 2 diabetes.

Purpose of the Study:

• To evaluate the safety and efficacy of glibenclamide in treating maturity onset diabetes mellitus.
• To compare the hypoglycemic potency of glibenclamide with other oral antidiabetic agents.

Main Methods:

• An initial clinical trial involving 28 patients with maturity onset diabetes mellitus.
• Treatment duration of up to one year with glibenclamide.
• Monitoring for toxic effects and side-effects.

Main Results:

• No toxic effects or side-effects were reported during the one-year treatment period.
• Glibenclamide demonstrated significant hypoglycemic potency.
• 5 mg of glibenclamide was equivalent to 1,500 mg of tolbutamide and 375 mg of chlorpropamide.

Conclusions:

• Glibenclamide appears to be a safe and effective treatment for maturity onset diabetes mellitus.
• Glibenclamide exhibits superior hypoglycemic potency compared to tolbutamide and chlorpropamide.
• Further investigation into glibenclamide for diabetes management is warranted.